.Attributes Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of clients with HER2+ sophisticated bosom cancer cells and active or even dependable human brain metastases revealed consistent intracranial task and also systemic efficacy of T-DXd.